J Crohns Colitis. 2026 Nov 7;20(11):jjag188. doi: 10.1093/ecco-jcc/jjag188.
ABSTRACT
BACKGROUND AND AIMS: The incidence of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is rising, particularly in middle-income countries. This study aims to identify biomarkers that predict the onset of IBD in a globally recruited population.
METHODS: Data from participants enrolled in the biomarker substudy of the Prospective Urban Rural Epidemiology (PURE) study were analyzed (discovery cohort). The primary outcome of interest was the development of incident IBD. Secondary outcomes were CD and UC. Protein concentration was measured using O-link® immuno-assays. Discovery analyses consisted of logistic regression models to evaluate the relationship between biomarker concentrations and risk of IBD. A separate analysis was conducted to validate biomarkers identified from the discovery cohort. Statistical significance was defined using a Bonferroni-corrected P < 1.6 × 10-5 for all analyses.
RESULTS: A total of 1011 biomarkers were assessed in the discovery cohort across 11 019 participants with n = 91 incident IBD cases. In the discovery analysis, elevated levels of matrix metalloproteinase-10 (MMP-10) were significantly associated with a future diagnosis of IBD (adjusted odds ratio [aOR] per SD: 1.75, 95% confidence interval [CI]: 1.40-2.18, P = 7.6 × 10-7). Results were consistent in direction for development of both UC and CD. In the validation analysis, MMP-10 remained significant for the outcome of IBD (aOR per SD: 2.41 [95% CI: 1.61-4.58], P = 5.2 × 10-6).
CONCLUSIONS: These findings suggest MMP-10 is a relevant biomarker in the general global population for prediction of clinical IBD, and further work should investigate its role in early detection and prevention strategies.
PMID:43034053 | PMC:PMC13769433 | DOI:10.1093/ecco-jcc/jjag188